Published in Br J Clin Pharmacol on October 01, 1976
Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol (1977) 1.17
Clinical pharmacology of labetalol. Br J Clin Pharmacol (1979) 1.09
Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J (1977) 1.08
Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol (1977) 0.95
Circulatory and alpha-adrenoceptor blocking effects of phentolamine. Br J Clin Pharmacol (1978) 0.91
Changes in heart rate and forearm blood flow following intravenous boluses of isoprenaline in the presence of practolol and propranolol. Br J Clin Pharmacol (1983) 0.88
Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties. Br J Clin Pharmacol (1984) 0.86
A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol (1979) 0.80
Effect of labetalol in hypertension during exercise and postural changes. Br J Clin Pharmacol (1979) 0.79
Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol (1982) 0.78
Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol. Br J Clin Pharmacol (1982) 0.78
Pharmacology of combined alpha-beta-blockade. I. Drugs (1984) 0.76
Management of ventricular arrhythmias associated with mitral valve prolapse by combined alpha and beta blockade. Postgrad Med J (1986) 0.75
Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis. J Am Heart Assoc (2017) 0.75
Treatment Strategies for Paradoxical Hypertension Following Surgical Correction of Coarctation of the Aorta in Children. World J Pediatr Congenit Heart Surg (2017) 0.75
A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS. Lancet (1964) 12.72
Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide). Lancet (1962) 8.89
Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol (1972) 4.53
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Beta-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline. Br J Clin Pharmacol (1975) 2.94
Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A. Br J Pharmacol (1972) 2.03
Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol (1975) 2.00
Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals. Br J Pharmacol (1975) 1.72
Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Clin Sci Mol Med Suppl (1975) 1.66
Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man. Clin Sci (1971) 1.41
Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension. Br Heart J (1974) 1.15
Circulatory effects of sympathomimetic amines. Am Heart J (1962) 1.03
Adrenoceptors and adenyl cyclase in gills. Br J Pharmacol (1973) 0.95
Treatment of hypertension with propranolol. Br Med J (1969) 8.21
Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison. Br Med J (1968) 3.89
Propranolol in the therapy of angina pectoris. Am J Cardiol (1966) 3.28
Calcium ions and the regulation of NAD+-linked isocitrate dehydrogenase from the mitochondria of rat heart and other tissues. Biochem J (1978) 2.38
Propranolol in hypertension. Am J Cardiol (1966) 2.28
Preoperative and operative management of patients with phaeochromocytoma. Br Med J (1967) 2.22
Pharmacologically effective plasma concentrations of ranitidine. Lancet (1979) 2.13
Use of propranolol in conjunction with alpha receptor blocking drugs in pheochromocytoma. Am J Cardiol (1966) 1.95
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet (1994) 1.89
Pharmacological effects of labetalol in man. Br J Clin Pharmacol (1976) 1.86
Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. Br Heart J (1971) 1.85
Complex hormonal regulation of rat casein gene expression. J Biol Chem (1982) 1.80
Labetalol in long-term treatment of hypertension. Br J Clin Pharmacol (1976) 1.73
Relationship between plasma concentrations and pharmacological effects of labetalol. Eur J Clin Pharmacol (1977) 1.71
Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J (1967) 1.68
Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J (1973) 1.68
Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Clin Sci Mol Med Suppl (1975) 1.66
Blood levels of practolol following intravenous administration. Br J Pharmacol (1970) 1.61
Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol (1991) 1.49
Ranitidine--a new H2-receptor antagonist. Gut (1980) 1.47
Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs (1974) 1.46
Skill mix between nurses and doctors working in primary care-delegation or allocation: a review of the literature. Int J Nurs Stud (2000) 1.42
Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man. Clin Sci (1971) 1.41
Dimensions of the human posterior septal space and coronary sinus. Am J Cardiol (1991) 1.40
Relationships between industry and units of clinical pharmacology. Br J Clin Pharmacol (1978) 1.39
Heat exhaustion in The Sun-Herald City to Surf fun run. Med J Aust (1994) 1.38
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 1.34
Proceedings: Preliminary observations on the human pharmacology of I.C.I. 66082 in normal volunteers. Br J Pharmacol (1973) 1.29
The treatment of hypertension by beta adrenergic blocking drugs. Angiologica (1966) 1.25
Double-blind trial of labetalol. Br J Clin Pharmacol (1976) 1.22
Clinical pharmacology: function, organisation, and training. Lancet (1971) 1.19
Construction and preliminary characterization of the rat casein and alpha-lactalbumin cDNA clones. J Biol Chem (1981) 1.18
Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol (1977) 1.17
Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol (1983) 1.17
The distribution of catecholamines between platelets and plasma in normal human subjects. Clin Sci (Lond) (1985) 1.14
The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol (1978) 1.11
Multihormonal regulation of casein gene expression at the transcriptional and posttransciptional levels in the mammary gland. Recent Prog Horm Res (1980) 1.10
Clinical pharmacology of labetalol. Br J Clin Pharmacol (1979) 1.09
Adrenoceptor blockade of the circulatory responses to intravenous isoproterenol. Clin Pharmacol Ther (1978) 1.08
Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J (1977) 1.08
Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience (2004) 1.08
Curative surgery for atrioventricular junctional ("AV nodal") reentrant tachycardia. J Am Coll Cardiol (1985) 1.07
Variation in the modification of cardiovascular responses by sympathetic inhibitory drugs. Proc R Soc Med (1969) 1.06
Post-marketing drug surveillance. Br J Clin Pharmacol (1978) 1.05
Effect of different degrees of tilt on cardiac output, heart rate, and blood pressure in normal man. Br Heart J (1966) 1.05
Labetalol and urinary catecholamines. Br Med J (1978) 1.05
The beta-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol (1983) 1.04
The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. Postgrad Med J (1970) 1.03
Overdosage with beta-adrenergic blocking agents. Adverse Drug React Acute Poisoning Rev (1984) 1.03
Once daily treatment of mild to moderate hypertension with xipamid: a controlled study. Br J Clin Pharmacol (1977) 1.03
Three cases of severe hypertension controlled with propranolol. Proc R Soc Med (1968) 1.03
Modification of pressor responses induced by 'cold' [proceedings]. Br J Clin Pharmacol (1977) 1.03
The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs. Br J Clin Pharmacol (1982) 1.02
beta Adrenergic blocking drugs. Pharmacol Ther (1980) 1.01
Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man. J Cardiovasc Pharmacol (1982) 0.99
Extremely large variations of atmospheric 14C concentration during the last glacial period. Science (2001) 0.98
Propranolol in the treatment of angina: a review. Postgrad Med J (1976) 0.98
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol (2015) 0.97
Isoprenaline-induced tachycardia in man. Br J Pharmacol (1972) 0.97
Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. Br J Clin Pharmacol (1990) 0.96
Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol (1977) 0.95
Extracellular neurotransmitter changes in cerebral ischaemia. Cerebrovasc Brain Metab Rev (1995) 0.95
Side-effects of ranitidine. Lancet (1982) 0.95
Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J (2009) 0.94
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) (2009) 0.93
Fish oils and cardiovascular disease. BMJ (1995) 0.93
Circulatory effects of noradrenaline and adrenaline before and after labetalol. Br J Clin Pharmacol (1979) 0.93
Long-term treatment of hypertension with labetalol. Br J Clin Pharmacol (1979) 0.92
Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. J Cardiovasc Pharmacol (1987) 0.92
Electrophysiologic substrate for ventricular tachycardia: correlation of properties in vivo and in vitro. Circulation (1984) 0.92
Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K+. J Neurochem (1994) 0.92
Restriction enzyme mapping and heteroduplex analysis of the rat milk protein cDNA clones. J Biol Chem (1981) 0.92
Circulatory and alpha-adrenoceptor blocking effects of phentolamine. Br J Clin Pharmacol (1978) 0.91
Combined alpha- and beta-receptor inhibition in the treatment of hypertension. Drugs (1984) 0.90
A controlled trial in travellers' diarrhoea. Practitioner (1970) 0.90
Size of family and behavioral problems in children. J Genet Psychol (1967) 0.90
Propranolol as an antihypertensive agent. Am Heart J (1970) 0.89
Prophylactic value of clioquinol against travellers' diarrhoea. Lancet (1971) 0.89
Effects of H1- and H2-receptor blocking agents on histamine-induced bronchoconstriction in non-asthmatic subjects. Br J Clin Pharmacol (1979) 0.89
A scale for assessing suicide risk of attempted suicides. J Clin Psychol (1968) 0.88
Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension. Br J Clin Pharmacol (1982) 0.88
Haemodynamic studies in hypertensive patients treated by oral proranolol. Br Heart J (1970) 0.87
Rate of onset of hypotensive response with oral labetalol [proceedings]. Br J Clin Pharmacol (1977) 0.87
Value of programmed stimulation and exercise testing in predicting one-year mortality after acute myocardial infarction. Am J Cardiol (1985) 0.87
Labetalol and urinary catecholamines. Br Med J (1979) 0.86
Factors related to attendance in a center for older people. J Am Geriatr Soc (1967) 0.86
The effect of intrinsic sympathomimetic activity on beta-receptor responsiveness after beta-adrenoceptor blockade withdrawal. Br J Clin Pharmacol (1982) 0.86
Concurrent antagonism of isoproterenol and norepinephrine after labetalol. Clin Pharmacol Ther (1978) 0.86
The effect of graded doses of practolol on the tachycardia induced by isoprenaline, Valsalva's manoeuvre and exercise. Br J Pharmacol (1970) 0.86
Does the induction of ventricular flutter or fibrillation at electrophysiologic testing after myocardial infarction have any prognostic significance? Am J Cardiol (1995) 0.85
A new protocol of programmed stimulation for assessment of predisposition to spontaneous ventricular arrhythmias. Eur Heart J (1983) 0.85